Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
(WJET/WFXP)– The City of Erie’s Redevelopment Authority announced a new program giving homeowners some financial help with demolishing old, blighted structures like detached garages on their property.
Tech Xplore on MSN
Smart composite combines ceramic strength with metal flexibility for large-scale manufacturing
Since his postdoctoral days at MIT, Hang Yu, associate professor of materials science and engineering, has been wrestling ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Research on the Influencing Factors and Configuration Paths of High-Quality Development of “Specialization, Refinement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback